Cough News and Research

RSS

Patheon announces fiscal 2009 fourth-quarter and full-year financial results

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for the fourth quarter and full year ended October 31, 2009.

18 Dec 2009

Researchers discover how protein can be controlled and under what circumstances it can go awry

A team of researchers studying the protein that, when defective or absent, causes cystic fibrosis (CF) has made an important discovery about how that protein is normally controlled and under what circumstances it might go awry.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

CHPA comments on NIDA's Monitoring the Future survey

Following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA), regarding today's release of the National Institute on Drug Abuse's (NIDA's) Monitoring the Future survey:

15 Dec 2009

TV and video games can provoke violence among school students

Middle-school students are expressing their views on the key factors affecting youth violence, with more than 30 percent of them indicating that television, video games, movies and music provoke violence.

15 Dec 2009

Supplements boost immune system and offer protection against seasonal flu

Accompanied by a chorus of coughs and sniffles, the winter season has arrived. "Protecting your health during this year's winter season should be a top priority for people," said Tom Tolworthy, CEO and Chief Health Enthusiast for The Vitamin Shoppe. "Many of our customers are being proactive in boosting their immune systems this time of year."

15 Dec 2009

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Scientists discover five genetic variants associated with lung disease

Scientists have discovered five genetic variants that are associated with the health of the human lung. The research by an international consortium of 96 scientists from 63 centres in Europe and Australia sheds new light on the molecular basis of lung diseases.

14 Dec 2009

Pertinent questions about H1N1 Influenza answered by NERAC

Municipalities in Massachusetts should assume that the H1N1 Influenza is now present in their communities, schools, and work places, and should take appropriate precautions to prevent the spread of this virus as well as the seasonal flu.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Patients' urine may provide rapid diagnosis of pneumonia

Doctors may soon be able to quickly and accurately diagnose the cause of pneumonia-like symptoms by examining the chemicals found in a patient's urine, suggests a new study led by UC Davis biochemist Carolyn Slupsky.

10 Dec 2009

Hi-Tech Pharmacal reports net sales of $40.9M for the quarter ended October 31, 2009

Hi-Tech Pharmacal Co., Inc. today reported results for the quarter ended October 31, 2009.

9 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

Cough News and Research

Patheon announces fiscal 2009 fourth-quarter and full-year financial results

Researchers discover how protein can be controlled and under what circumstances it can go awry

Brachytherapy for lung cancer

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

FDA Advisory Committee votes against the approval of Tarceva

CHPA comments on NIDA's Monitoring the Future survey

TV and video games can provoke violence among school students

Supplements boost immune system and offer protection against seasonal flu

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

ZYPREXA RELPREVV approved by FDA

Scientists discover five genetic variants associated with lung disease

Pertinent questions about H1N1 Influenza answered by NERAC

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Patients' urine may provide rapid diagnosis of pneumonia

Hi-Tech Pharmacal reports net sales of $40.9M for the quarter ended October 31, 2009

VERTICAL Phase II trial results for NHL released

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

TMZ and small molecule combination appears to lower tumor resistance

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News